Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt

References

• Ibrahim AS, Khaled HM, Mikhail NN, et al. Cancer incidence in Egypt: results of the national population-based cancer registry program. J. Cancer Epidemiol. 2014;2014. Article ID 437971.
   PubMedGoogle Scholar
• Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol. 2010;23:S60–S64.
   PubMed Web of Science ®Google Scholar
• Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 2013;8:135–155.
   PubMedGoogle Scholar
• Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320–368.
   PubMed Web of Science ®Google Scholar
• Farouk O, Ebrahim MA, Senbel A, et al. Breast cancer characteristics in very young Egyptian women ≤35 years. Breast Cancer Targets Ther. 2016;8:53–58.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672.
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–1283.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–1205.
   PubMed Web of Science ®Google Scholar
• Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32:3744–3752.
   PubMed Web of Science ®Google Scholar
• Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12:236–244.
   PubMed Web of Science ®Google Scholar
• Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14:741–748.
   PubMed Web of Science ®Google Scholar
• Earl HM, Cameron DA, Miles D, et al. PERSEPHONE: duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer – six versus twelve months. J Clin Oncol. 2014;32:TPS667.
   Web of Science ®Google Scholar
• Mavroudis D, Saloustros E, Malamos N, et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2015;26:1333–1340.
   PubMed Web of Science ®Google Scholar
• Conte P, Frassoldati A, Bisagni G, et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study double dagger. Ann Oncol. 2018;29:2328–2333.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Fraser J, Wildiers H, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial. JAMA Oncol. 2018;4:1199–1206.
   PubMed Web of Science ®Google Scholar
• Schneider BP, O'Neill A, Shen F, et al. Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer. 2015;113:1651–1657.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Brien BO, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health. 2003;6:9–17.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.
   PubMed Web of Science ®Google Scholar
• Elsisi GH, Kaló Z, Eldessouki R, et al. Recommendations for reporting pharmacoeconomic evaluations in Egypt. Value Health RI. 2013;2:319–327.
   Google Scholar
• Tanis E, van de Velde CJH, Bartelink H, et al. Locoregional relapse after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer. Eur J Cancer. 2012;48:1751–1756.
   PubMed Web of Science ®Google Scholar
• Pérez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366–3373.
   PubMed Web of Science ®Google Scholar
• Buendía JA, Vallejos C, Pichón-Rivière A. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia. Biomedica. 2013;33:411–417.
   PubMed Web of Science ®Google Scholar
• Earl HM, Hiller L, Vallier AL, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019;393:2599–2612.
   PubMed Web of Science ®Google Scholar
• Lidgren M, Wilking N, Jonsson B, et al. Health-related quality of life in different states of breast cancer. Qual Life Res. 2007;16:1073–1081.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95:683–690.
   PubMed Web of Science ®Google Scholar
• Calvert MJ, Freemantle N, Cleland J. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail. 2005;7:243–251.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) – explanation and elaboration: are part of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16:231–250.
   PubMed Web of Science ®Google Scholar
• Ansaripour A, Uyl-de Groot CA, Redekop WK. Adjuvant trastuzumab therapy for early HER2-positive breast cancer in Iran: a cost-effectiveness and scenario analysis for an optimal treatment strategy. Pharmacoeconomics. 2017;36:91–103.
   Web of Science ®Google Scholar
• Chen W, Jiang Z, Shao Z, et al. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health. 2009;12:S82–S84.
   PubMed Web of Science ®Google Scholar
• Van Vlaenderen I, Canon JL, Cocquyt V, et al. Trastuzumab treatment of early stage breast cancer is cost effective from the perspective of the Belgian health care authorities. Acta Clin Belg. 2009;64:100–112.
   PubMed Web of Science ®Google Scholar
• Kurian AW, Thompson RN, Gaw AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu – positive breast cancer. J Clin Oncol. 2007;25:634–641.
   PubMed Web of Science ®Google Scholar
• Garrison LP, Lubeck D, Lalla D, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007;110:489–498.
   PubMed Web of Science ®Google Scholar
• Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomics. 2007;25:429–442.
   PubMed Web of Science ®Google Scholar
• Hall P, Hulme C, McCabe C, et al. Updated cost-effectiveness analysis of trastuzumab for early breast cancer. Pharmacoeconomics. 2011;29:415–432.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. New York: Oxford University Press; 2015.
   Google Scholar